Supernus Pharma (SUPN) Misses Q4 EPS by 48c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Join SI Premium – FREE
Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.07), $0.48 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $211.6 million versus the consensus estimate of $195.48 million.
GUIDANCE:
Supernus Pharma sees FY2026 revenue of $840-870 million, versus the consensus of $861.2 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
